Cargando…
Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
Neonatal herpes is a dreaded complication of genital herpes infection in pregnancy. We recently compared two vaccine platforms for preventing genital herpes in female mice and guinea pigs and determined that HSV-2 glycoproteins C, D and E expressed using nucleoside-modified mRNA in lipid nanoparticl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545304/ https://www.ncbi.nlm.nih.gov/pubmed/33041105 http://dx.doi.org/10.1016/j.vaccine.2020.09.079 |
_version_ | 1783592006548717568 |
---|---|
author | LaTourette, Philip C. Awasthi, Sita Desmond, Angela Pardi, Norbert Cohen, Gary H. Weissman, Drew Friedman, Harvey M. |
author_facet | LaTourette, Philip C. Awasthi, Sita Desmond, Angela Pardi, Norbert Cohen, Gary H. Weissman, Drew Friedman, Harvey M. |
author_sort | LaTourette, Philip C. |
collection | PubMed |
description | Neonatal herpes is a dreaded complication of genital herpes infection in pregnancy. We recently compared two vaccine platforms for preventing genital herpes in female mice and guinea pigs and determined that HSV-2 glycoproteins C, D and E expressed using nucleoside-modified mRNA in lipid nanoparticles provided better protection than the same antigens produced as baculovirus proteins and administered with CpG and alum. Here we evaluated mRNA and protein immunization for protection against neonatal herpes. Female mice were immunized prior to mating and newborns were infected intranasally with HSV-2. IgG binding and neutralizing antibody levels in mothers and newborns were comparable using the mRNA or protein vaccines. Both vaccines protected first and second litter newborns against disseminated infection based on virus titers in multiple organs. We conclude that both vaccines are efficacious at preventing neonatal herpes, which leaves the mRNA vaccine as our preferred candidate based on better protection against genital herpes. |
format | Online Article Text |
id | pubmed-7545304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75453042020-10-09 Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine LaTourette, Philip C. Awasthi, Sita Desmond, Angela Pardi, Norbert Cohen, Gary H. Weissman, Drew Friedman, Harvey M. Vaccine Short Communication Neonatal herpes is a dreaded complication of genital herpes infection in pregnancy. We recently compared two vaccine platforms for preventing genital herpes in female mice and guinea pigs and determined that HSV-2 glycoproteins C, D and E expressed using nucleoside-modified mRNA in lipid nanoparticles provided better protection than the same antigens produced as baculovirus proteins and administered with CpG and alum. Here we evaluated mRNA and protein immunization for protection against neonatal herpes. Female mice were immunized prior to mating and newborns were infected intranasally with HSV-2. IgG binding and neutralizing antibody levels in mothers and newborns were comparable using the mRNA or protein vaccines. Both vaccines protected first and second litter newborns against disseminated infection based on virus titers in multiple organs. We conclude that both vaccines are efficacious at preventing neonatal herpes, which leaves the mRNA vaccine as our preferred candidate based on better protection against genital herpes. Elsevier Ltd. 2020-11-03 2020-10-09 /pmc/articles/PMC7545304/ /pubmed/33041105 http://dx.doi.org/10.1016/j.vaccine.2020.09.079 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication LaTourette, Philip C. Awasthi, Sita Desmond, Angela Pardi, Norbert Cohen, Gary H. Weissman, Drew Friedman, Harvey M. Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine |
title | Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine |
title_full | Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine |
title_fullStr | Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine |
title_full_unstemmed | Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine |
title_short | Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine |
title_sort | protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mrna in lipid nanoparticle vaccine |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545304/ https://www.ncbi.nlm.nih.gov/pubmed/33041105 http://dx.doi.org/10.1016/j.vaccine.2020.09.079 |
work_keys_str_mv | AT latourettephilipc protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine AT awasthisita protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine AT desmondangela protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine AT pardinorbert protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine AT cohengaryh protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine AT weissmandrew protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine AT friedmanharveym protectionagainstherpessimplexvirustype2infectioninaneonatalmurinemodelusingatrivalentnucleosidemodifiedmrnainlipidnanoparticlevaccine |